Isolation of antibody set for anticancer agents and development of novel cancer model rat for evaluation of them.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K06884
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Fujita Health University
• Principal Investigator: Kuosawa Gene 藤田保健衛生大学, 研究支援推進センター, 講師 (10410739)
• Research Collaborator: TSUDA Hiroyuki 名古屋市立大学, 教授 ; OKA Chieko
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: がん / がん周辺微小環境 / ヒトRas変異 / 抗体評価系 / ヒト抗体 / 免疫 / モデル動物 / 免疫寛容

Outline of Final Research Achievements

This project aim to develop the next generation human monoclonal antibodies, using spontaneous tumorigenesis rat model via mutated Ras over expression. Currently an immune check point are most important concept for development of anti cancer monoclonal antibody agents. In this regards, the immune check point inhibitor were strongly expected to be next generation anti cancer agents. On the other hand, the evaluation system for these agent are still limited such as a Syngenic grafting model. Therefore this project try to solve this matter using the spontaneous tumorigenesis rat model. Thus, we have isolated antibody set for anticancer agents and development of novel cancer model rat for evaluation of them.

Free Research Field

腫瘍免疫学